

## PRESS RELEASE

Stockholm, Sweden, 4 February 2020



### Invitation – Presentation of Sobi's Q4/FY 2019 results

On 13 February, at 08:00 CET, [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) will publish its report for the fourth quarter and full-year 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 10:00 am CET. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on [www.sobi.com](http://www.sobi.com). Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46 8 505 583 55

UK: +44 333 300 9272

US: +1 646 722 4902

[Click here to go to the live webcast.](#)

*After the live event the webcast will be available on-demand via the same URL.*

---

#### About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,300 people across Europe, North America, the Middle East, Russia and North Africa. In 2018, Sobi's revenue amounted to SEK 9.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at [sobi.com](http://sobi.com).

#### For more information please contact

Paula Treutiger, Head of Communication & Investor Relations

+ 46 733 666 599

[paula.treutiger@sobi.com](mailto:paula.treutiger@sobi.com)

Linda Holmström, Corporate Communication & Investor Relations

+ 46 708 734 095

[linda.holmstrom@sobi.com](mailto:linda.holmstrom@sobi.com)